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| INTRODUC TI ON
Prostate cancer, ranked as the second most frequent cancer in men worldwide, attacks roughly 1.3 million people and leads to 359 000 deaths in 2018 according to the most recent global cancer statistical report. 1 Diagnosis of prostate cancer mainly bases on biopsy, and although new imaging technology has been progressed to enhance the diagnostic accuracy, effective screening and timely diagnosis are still insufficient. [2] [3] [4] Treatment of prostate cancer has sufficiently progressed, while, for the early stage patients presenting with good response to treatment and favorable survival, they often suffer from sequelae or adverse events. As for the patients in late stage with unsatisfactory response to treatment, their survival profile is still poor. [5] [6] [7] Therefore, it is necessary to explore more biomarkers, which could assist with the management of prostate cancer.
Circular RNAs (circRNAs), a novel class of non-coding RNAs presenting with closed loops without poly A tails, are stably expressed in human and have almost no protein-coding function. 8 In recent years, circRNAs have been revealed as genetic factors that play critical roles in various cancers, such as promoting cancer progression by regulating cancer cell functions and presenting with potential as prognostic biomarkers. [9] [10] [11] Additionally, circRNAs are increasingly implicated in prostate cancer as well; however, the relevant studies are not as abundant as the studies of other cancers. 12, 13 Circular RNA-mitochondrial tRNA translation optimization 1 (circ-MTO1) is a novel circRNA that is previously reported as an anti-tumor gene, which inhibits liver fibrosis to prevent hepatocellular carcinoma and represses progression of lung cancer and breast cancer. 14, 15 And circ-MTO1 has also been reported to express in prostate cancer (http://www.circb ase.org/), Based on these facts, we supposed that circ-MTO1 might play a crucial role in prostate cancer.
Thus, the aim of this study was to investigate circ-MTO1 expression in tumor tissue and its correlation with clinical characteristics, survival profiles, as well as its effect on cancer cell functions in prostate cancer. (e) can be followed up regularly. Besides, the patients complicated with other malignancies were excluded. This study was approved by the Ethics Committee of our hospital and conducted according to the Declaration of Helsinki. All patients signed the informed consents before enrollment.
| MATERIAL S AND ME THODS

| Patients
| Data and sample collection
The major tumor characteristics of patients were recorded including Gleason score, pathological T stage, pathological N stage, surgical margin status and prostate-specific antigen (PSA) level. The fresh tumor tissue and paired adjacent tissue excised from surgery were divided into two parts. One was sent to the pathology department for routine pathologic analysis, and the other was snap-frozen and used for circ-MTO1 (access number: has_circ_0076979) determination in this study. And the relative expression of circ-MTO1 in tumor tissue and adjacent tissue was detected by reverse transcriptionquantitative polymerase chain reaction (RT-qPCR).
| Treatment and follow-up
After enrollment, preoperative treatments were administered to patients as appropriate based on the patients' clinical status, then surgery was carried out. After surgery, conventional care and adjuvant therapy were given to patients as well, and both the preoperative treatment and the adjuvant therapy were conducted according to the guideline, 16 Overall survival (OS) was calculated from the date of entry into the study to the date of death. For patients not known to have died at last follow-up, they were censored on the date of last known to be alive. 
| Cell culture
| Transfection and assays
| RT-qPCR
In the beginning, the RNA extraction from tissues and cells was carried out by RNeasy Protect Mini Kit (Qiagen) according to the instructions of the manufacturer. Then for circ-MTO1 detection, the linear RNA was digested using RNase R (Epicentre), while for miR-17-5p and miR-630 detection the linear RNA was not digested.
Subsequently, the RNA was reversely transcribed into cDNA by the iScript cDNA Synthesis Kit (Bio-Rad), afterward, PCR was performed by QuantiNova SYBR Green PCR Kit (Qiagen). Then, the relative expressions of circ-MTO1 and miR-17-5p/miR-630 were calculated using the formula 2 −ΔΔCt . Besides, the internal reference for circ-MTO1 was GAPDH, and the internal reference for miR-17-5p as well as miR-630 was U6. And before the detection of GAPDH, the linear RNA was digested by RNase R (Epicentre).
In addition, all the primers used in RT-qPCR were as follows: 
| Statistical analysis
| RE SULTS
| Baseline characteristics
The mean age was 62.0 ± 9.5 years in patients with prostate cancer enrolled in our study ( 
| Expression of circ-MTO1 in tumor tissue and paired adjacent tissue
The expression of circ-MTO1 in tumor tissue and paired adjacent tissue was detected by RT-qPCR, which displayed that circ-MTO1 expression was lower in tumor tissue compared with paired adjacent tissue in prostate cancer patients (P < .001) (Figure 1 ).
| Correlation of circ-MTO1 expression in tumor tissue with clinical features
The circ-MTO1 high expression in tumor tissue was correlated with decreased pathological T stage (P = .001) and lower pathological N stage (P = .020) in patients with prostate cancer, while it was not associated with age (P = .345), Gleason score (P = .793), surgical margin status (P = .185) or PSA level (P = .806) ( Table 2 ).
| Correlation of tumor tissue circ-MTO1 with survival profiles
The DFS was more favorable in patients who had circ-MTO1 high expression in tumor tissue compared with prostate cancer patients who had circ-MTO1 low expression (P = .006) ( Figure 2A ), and the OS was also longer in patients with circ-MTO1 high expression than that in patients with circ-MTO1 low expression (P = .018) ( Figure 2B ). (Table 4 ). Subsequently, all the factors were analyzed by multivariate Cox's regression analysis, which illustrated that circ-MTO1 high expression (P = .044) independently predicted more prolonged OS, while higher Gleason score (P < .001), higher pathological N stage (P = .028), positive surgical margin (P = .020), and higher PSA level (P = .013) were independent predictive factors for less satisfactory OS.
| Effect of circ-MTO1 on prostate cancer cell proliferation and invasion as well as its potential target miRNA
The circ-MTO1 expression was downregulated in DU-145 cells Figure 3G ) was of no difference between the two groups.
| D ISCUSS I ON
In this study, we discovered that (a) circ-MTO1 expression was the expression of forkhead box P4. 12 Another study reveals that circ_0001206 is decreased in prostate cancer tumor tissue and represses cell proliferation, migration and invasion in prostate cancer cells. 17 Additionally, a recent research discloses that the decreased circ-itchy E3 ubiquitin-protein ligase associates with more severe pathological T stage, increased lymph node metastasis risk and worse survival in patients with prostate cancer. 18 In terms of the specific circRNA (circ-MTO1) evaluated in our study, the circ-MTO1, it has not been studied in prostate cancer before. However, there have been several studies demonstrate the 
TA B L E 3 Analysis of factors predicting DFS
anti-oncogenetic role of circ-MTO1 in other cancers. For example, a previous in vitro study reports that circ-MTO1/miR-17/QKI-5 regulatory circuit suppresses lung cancer cell proliferation. 19 Furthermore, circ-MTO1 inhibits cancer cell viability and reverses the resistance to monastrol in breast cancer cells. 15 In this study, we found that circ-MTO1 was downregulated in tumor tissue provide some explanation to these results. b) Circ-MTO1 might also inhibit prostate cancer progression by repressing chemoresistance, which contributed to a better treatment response and subsequent favorable survival. 15, 19 Increasing information about the effect of circRNAs on cancer cell functions in prostate cancer has been revealed recently.
For example, circ-SMARCA5 is an androgen-responsive circRNA that is overexpressed and enhances cell proliferation in prostate cancer cells. 20 And circ-nyosin light chain kinase enhances prostate cancer cell proliferation, invasion and migration by mediating the level of miR-29a. 21 Although the detailed mechanism of circ-MTO1 in mediating cell activities in prostate cancer has not been investigated in our study, we observed that circ-MTO1 in- Furthermore, there were several limitations in this study: (a) the follow-up duration was relatively short, which should be prolonged in the future; we only assessed the expression of circ-MTO1 in tumor tissue but not in circulating samples that were more convenient considering the clinical utility, such as plasma or serum, which should be evaluated in the future study; (b) patients enrolled in this study were prostate cancer patients who had underwent resection; therefore, the role of circ-MTO1 in unresectable prostate cancer patients was unclear.
In conclusion, circ-MTO1 correlates with decreased pathological T/N stage and favorable survival profiles, and it also inhibits cell proliferation, invasion as well as miR-17-5p expression in prostate cancer.
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